Group items tagged

Vitamin K2. Monograph. [No authors listed] Altern Med Rev. 2009 Sep;14(3):284-93. Review. PMID: 19803553

Role of vitamin K2 in the treatment of postmenopausal osteoporosis. Iwamoto J, Takeda T, Sato Y. Curr Drug Saf. 2006 Jan;1(1):87-97. Review. PMID: 18690918

Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women. Koitaya N, Ezaki J, Nishimuta M, Yamauchi J, Hashizume E, Morishita K, Miyachi M, Sasaki S, Ishimi Y. J Nutr Sci Vitaminol (Tokyo). 2009 Feb;55(1):15-21. PMID: 19352059 It has been reported that treatment with a pharmacological dose (45 mg/d) of menaquinone-4 (MK-4) prevents bone loss in postmenopausal women. However, it is not known whether supplementation with low dose MK-4 has beneficial effects on bone metabolism in healthy women. The aim of this study is to examine the effects of the supplementation of 1.5 mg/d MK-4 for 4 wk on bone and lipid metabolism in healthy postmenopausal Japanese women. The study was performed as a randomized double blind placebo-controlled trial. The participants aged 53-65 y were randomly assigned to 2 groups and supplemented with 1.5 mg/d of MK-4 or a placebo for 4 wk (n=20 for each group). The most marked effects of MK-4 intake were observed on serum osteocalcin (OC) concentrations. Serum undercarboxylated OC (ucOC) concentration decreased, and the gamma-carboxylated OC (GlaOC) and GlaOC/GlaOC+ucOC ratio that indicates the degree of OC gamma-carboxylation increased significantly at 2 and 4 wk compared with that at baseline in the MK-4 group. The serum ucOC and GlaOC concentrations in the MK-4 group were significantly different from those in the placebo group at 2 wk. These results suggest that supplementation with 1.5 mg/d MK-4 accelerated the degree of OC gamma-carboxylation. The concentrations of serum lipids and other indices were not different between the groups at either intervention period. Thus, the additional intake of MK-4 might be beneficial in the maintenance of bone health in postmenopausal Japanese women.

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15. PMID: 19501932 CONCLUSIONS: The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization.

Strong correlations have been noted between cardiovascular diseases and low bone density / osteoporosis-connections so strong that the presence of one is considered a likely predictor of the other. This relationship has led to the hypothesis that these conditions share core pathophysiological mechanisms. Recent advances in our understanding of the complimentary roles played by vitamin D3 and vitamin K2 in vascular and bone health provide support for this hypothesis, along with insight into key metabolic dysfunctions underlying cardiovascular disease and osteoporosis. Part II, The Vitamin K Connection to Cardiovascular Health, reviews the ways in which vitamin K regulates calcium utlization, preventing vascular and soft tissue calcification while complimenting the bone-building actions of vitamin D, and also discusses vitamin K safety and dosage issues, and the necessity of providing vitamin K and vitamin A along with vitamin D to preclude adverse effects associated with hypervitaminosis D.

Strong correlations have been noted between cardiovascular diseases and low bone density / osteoporosis-connections so strong that the presence of one type of pathology is considered a likely predictor of the other. This potentially causal relationship has led to the hypothesis that these conditions share core mechanisms. Recent advances in our understanding of the complimentary roles played by vitamin D3 and vitamin K2 in vascular and bone health provide support for this hypothesis, along with insight into key metabolic dysfunctions underlying cardiovascular disease and osteoporosis. Part I of this review summarizes current research linking vitamin D deficiency to cardiovascular disease, the physiological mechanisms underlying vitamin D's cardiovascular effects, and leading vitamin D researchers' recommendations for significantly higher supplemental doses of the pro-hormone. Part II reviews the vitamin K connection to cardiovascular disease; the ways in which vitamin D and vitamin K pair up to prevent inflammation, vascular calcification and osteoporosis; and the necessity of providing vitamin K along with vitamin D to preclude adverse effects associated with hypervitaminosis D, which include vascular and other soft tissue calcification.

High dietary menaquinone intake is associated with reduced coronary calcification.\nBeulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC, Grobbee DE, van der Schouw YT.\nAtherosclerosis. 2008 Jul 19. [Epub ahead of print]\nPMID: 18722618 \ndoi:10.1016/j.atherosclerosis.2008.07.010 \n

Dietary supplementation with fermented soybeans suppresses intimal thickening. Suzuki Y, Kondo K, Ichise H, Tsukamoto Y, Urano T, Umemura K. Nutrition. 2003 Mar;19(3):261-4. PMID: 12620531

Promotion of bone formation by fermented soybean (Natto) intake in premenopausal women.\nKatsuyama H, Ideguchi S, Fukunaga M, Fukunaga T, Saijoh K, Sunami S.\nJ Nutr Sci Vitaminol (Tokyo). 2004 Apr;50(2):114-20.\nPMID: 15242015

Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7.\nSchurgers LJ, Teunissen KJ, Hamulyák K, Knapen MH, Vik H, Vermeer C.\nBlood. 2007 Apr 15;109(8):3279-83. Epub 2006 Dec 7.\nPMID: 17158229 \nDOI 10.1182/blood-2006-08-040709\n

Vitamin K in the treatment and prevention of osteoporosis and arterial calcification.\nAdams J, Pepping J.\nAm J Health Syst Pharm. 2005 Aug 1;62(15):1574-81. Review.\nPMID: 16030366

Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study.\nGeleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC.\nJ Nutr. 2004 Nov;134(11):3100-5.\nPMID: 15514282

Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg).\nNimptsch K, Rohrmann S, Linseisen J.\nAm J Clin Nutr. 2008 Apr;87(4):985-92.\nPMID: 18400723

Vitamin K is a fat-soluble vitamin. The "K" is derived from the German word "koagulation." Coagulation refers to the process of blood clot formation. Vitamin K is essential for the functioning of several proteins involved in blood clotting (1). There are two naturally occurring forms of vitamin K

The vitamin K dependant protein osteocalcin may have a positive effect on reducing obesity and diabetes, suggests a new study with mice.\nResearchers writing in the journal Cells studied the effect bone cells have in energy regulation, and found that osteocalcin plays a key role in regulating insulin activity.

A high menaquinone reduces the incidence of coronary heart disease in women.\nGast GC, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, Witteman JC, Grobbee DE, Peeters PH, van der Schouw YT.\nNutr Metab Cardiovasc Dis. 2009 Jan 27. [Epub ahead of print]\nPMID: 19179058 \ndoi: 10.1016/j.numecd.2008.10.004\n

Determination of Phylloquinone and Menaquinones in Foods by HPLC\n\nTerhi Koivu-Tikkanen\n\nAcademic Dissertation, January 2001. \nUniversity of Helsinki, Faculty of Agriculture and Forestry, \nDepartment of Applied Chemistry and Microbiology

Quantitative measurement of tetrahydromenaquinone-9 in cheese fermented by propionibacteria.\nHojo K, Watanabe R, Mori T, Taketomo N.\nJ Dairy Sci. 2007 Sep;90(9):4078-83.\nPMID: 17699024 \ndoi:10.3168/jds.2006-892\n